Substance / Medication

Rivastigmine tartrate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
Thomas Saji, Shandilya Sanjeev, Bharati Amber et al. · J Pharm Biomed Anal · 2012
PMID: 21880452Observational
Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes Keith · Drugs Today (Barc) · 2007
PMID: 17612707Review
Synthesis and characterization of a novel molecularly imprinted polymer for the controlled release of rivastigmine tartrate.
Torabi Seyed Javad, Mohebali Alireza, Abdouss Majid et al. · Mater Sci Eng C Mater Biol Appl · 2021
PMID: 34474832Other
MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy.
Shamsi Anas, Anwar Saleha, Mohammad Taj et al. · Biomolecules · 2020
PMID: 32443670OtherFull text (PMC)
Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
Nieto Rachel A, Deardorff William James, Grossberg George T · Expert Opin Pharmacother · 2016
PMID: 26918774Other
Unsubstantiated superiority claims for rivastigmine tartrate.
Shah Shiwan K, Krueger Paul M · J Am Osteopath Assoc · 2006
PMID: 17122027Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rivastigmine tartrate (substance)
SNOMED CT
126131008
UMLS CUI
C0772415

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Rivastigmine tartrate — Conditions, Biomarkers & Specialists | Healos | Healos